nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PPARG—obesity	0.347	0.703	CbGaD
Mesalazine—PTGS2—obesity	0.147	0.297	CbGaD
Mesalazine—PPARG—brown adipose tissue—obesity	0.00688	0.0962	CbGeAlD
Mesalazine—PTGS2—ovarian follicle—obesity	0.00532	0.0744	CbGeAlD
Mesalazine—CHUK—cardiovascular system—obesity	0.00249	0.0348	CbGeAlD
Mesalazine—IKBKB—respiratory system—obesity	0.00221	0.0309	CbGeAlD
Mesalazine—CHUK—adipose tissue—obesity	0.00219	0.0307	CbGeAlD
Mesalazine—CHUK—digestive system—obesity	0.00207	0.0289	CbGeAlD
Mesalazine—CHUK—adrenal gland—obesity	0.00197	0.0275	CbGeAlD
Mesalazine—ALOX5—islet of Langerhans—obesity	0.00194	0.0271	CbGeAlD
Mesalazine—ALOX5—respiratory system—obesity	0.00183	0.0256	CbGeAlD
Mesalazine—CHUK—endocrine gland—obesity	0.00171	0.0239	CbGeAlD
Mesalazine—IKBKB—cardiovascular system—obesity	0.00169	0.0237	CbGeAlD
Mesalazine—MPO—respiratory system—obesity	0.00155	0.0217	CbGeAlD
Mesalazine—CHUK—liver—obesity	0.00154	0.0215	CbGeAlD
Mesalazine—IKBKB—pituitary gland—obesity	0.0015	0.021	CbGeAlD
Mesalazine—IKBKB—adipose tissue—obesity	0.00149	0.0209	CbGeAlD
Mesalazine—PPARG—islet of Langerhans—obesity	0.00146	0.0204	CbGeAlD
Mesalazine—IKBKB—digestive system—obesity	0.0014	0.0196	CbGeAlD
Mesalazine—ALOX5—cardiovascular system—obesity	0.0014	0.0196	CbGeAlD
Mesalazine—PPARG—respiratory system—obesity	0.00137	0.0192	CbGeAlD
Mesalazine—IKBKB—adrenal gland—obesity	0.00134	0.0187	CbGeAlD
Mesalazine—ALOX5—adipose tissue—obesity	0.00124	0.0173	CbGeAlD
Mesalazine—MPO—cardiovascular system—obesity	0.00119	0.0166	CbGeAlD
Mesalazine—ALOX5—digestive system—obesity	0.00116	0.0163	CbGeAlD
Mesalazine—IKBKB—endocrine gland—obesity	0.00116	0.0162	CbGeAlD
Mesalazine—PTGS2—gall bladder—obesity	0.00113	0.0159	CbGeAlD
Mesalazine—ALOX5—adrenal gland—obesity	0.00111	0.0155	CbGeAlD
Mesalazine—PPARG—cardiovascular system—obesity	0.00105	0.0147	CbGeAlD
Mesalazine—MPO—pituitary gland—obesity	0.00105	0.0147	CbGeAlD
Mesalazine—IKBKB—liver—obesity	0.00105	0.0146	CbGeAlD
Mesalazine—MPO—digestive system—obesity	0.000985	0.0138	CbGeAlD
Mesalazine—ALOX5—endocrine gland—obesity	0.000962	0.0135	CbGeAlD
Mesalazine—MPO—adrenal gland—obesity	0.000938	0.0131	CbGeAlD
Mesalazine—Olsalazine—IFNG—obesity	0.000933	0.155	CrCbGaD
Mesalazine—PPARG—adipose tissue—obesity	0.000928	0.013	CbGeAlD
Mesalazine—PPARG—digestive system—obesity	0.000874	0.0122	CbGeAlD
Mesalazine—ALOX5—liver—obesity	0.000867	0.0121	CbGeAlD
Mesalazine—PPARG—adrenal gland—obesity	0.000833	0.0116	CbGeAlD
Mesalazine—MPO—endocrine gland—obesity	0.000814	0.0114	CbGeAlD
Mesalazine—PTGS2—islet of Langerhans—obesity	0.000744	0.0104	CbGeAlD
Mesalazine—PTGS1—respiratory system—obesity	0.000735	0.0103	CbGeAlD
Mesalazine—MPO—liver—obesity	0.000734	0.0103	CbGeAlD
Mesalazine—PPARG—endocrine gland—obesity	0.000722	0.0101	CbGeAlD
Mesalazine—PTGS2—respiratory system—obesity	0.000702	0.00983	CbGeAlD
Mesalazine—PPARG—liver—obesity	0.000651	0.00911	CbGeAlD
Mesalazine—PTGS2—adrenal cortex—obesity	0.000589	0.00825	CbGeAlD
Mesalazine—Methyldopa—COMT—obesity	0.000576	0.0959	CrCbGaD
Mesalazine—PTGS1—cardiovascular system—obesity	0.000563	0.00787	CbGeAlD
Mesalazine—PTGS2—cardiovascular system—obesity	0.000538	0.00753	CbGeAlD
Mesalazine—Droxidopa—ADRB3—obesity	0.000506	0.0842	CrCbGaD
Mesalazine—PTGS1—pituitary gland—obesity	0.000498	0.00697	CbGeAlD
Mesalazine—PTGS1—adipose tissue—obesity	0.000496	0.00694	CbGeAlD
Mesalazine—PTGS2—pituitary gland—obesity	0.000476	0.00666	CbGeAlD
Mesalazine—PTGS2—adipose tissue—obesity	0.000474	0.00664	CbGeAlD
Mesalazine—PTGS1—digestive system—obesity	0.000467	0.00654	CbGeAlD
Mesalazine—PTGS2—digestive system—obesity	0.000446	0.00625	CbGeAlD
Mesalazine—PTGS1—adrenal gland—obesity	0.000445	0.00623	CbGeAlD
Mesalazine—Olsalazine—PPARG—obesity	0.00044	0.0731	CrCbGaD
Mesalazine—PTGS2—adrenal gland—obesity	0.000425	0.00595	CbGeAlD
Mesalazine—PTGS1—endocrine gland—obesity	0.000386	0.0054	CbGeAlD
Mesalazine—PTGS2—endocrine gland—obesity	0.000369	0.00516	CbGeAlD
Mesalazine—PTGS2—liver—obesity	0.000333	0.00465	CbGeAlD
Mesalazine—Dopamine—COMT—obesity	0.000281	0.0468	CrCbGaD
Mesalazine—Salicylate-sodium—PTGS2—obesity	0.000271	0.045	CrCbGaD
Mesalazine—L-DOPA—DRD4—obesity	0.000245	0.0408	CrCbGaD
Mesalazine—Dopamine—SLC22A1—obesity	0.000236	0.0393	CrCbGaD
Mesalazine—Droxidopa—ADRB1—obesity	0.000229	0.0381	CrCbGaD
Mesalazine—Dopamine—DRD4—obesity	0.000228	0.0379	CrCbGaD
Mesalazine—L-DOPA—DRD1—obesity	0.000208	0.0345	CrCbGaD
Mesalazine—Dopamine—DRD1—obesity	0.000193	0.0321	CrCbGaD
Mesalazine—Droxidopa—ADRB2—obesity	0.000193	0.032	CrCbGaD
Mesalazine—Olsalazine—PTGS2—obesity	0.000186	0.0309	CrCbGaD
Mesalazine—Dopamine—ADRB1—obesity	0.000179	0.0298	CrCbGaD
Mesalazine—Diflunisal—PTGS2—obesity	0.000174	0.029	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—obesity	0.000174	0.029	CrCbGaD
Mesalazine—Diflunisal—ALB—obesity	0.000155	0.0259	CrCbGaD
Mesalazine—L-DOPA—DRD2—obesity	0.000146	0.0244	CrCbGaD
Mesalazine—Chest pain—Sibutramine—obesity	0.000139	0.000592	CcSEcCtD
Mesalazine—Myalgia—Sibutramine—obesity	0.000139	0.000592	CcSEcCtD
Mesalazine—Anxiety—Sibutramine—obesity	0.000138	0.00059	CcSEcCtD
Mesalazine—Nervousness—Bupropion—obesity	0.000138	0.000588	CcSEcCtD
Mesalazine—Oedema—Orlistat—obesity	0.000137	0.000586	CcSEcCtD
Mesalazine—Anaphylactic shock—Orlistat—obesity	0.000137	0.000586	CcSEcCtD
Mesalazine—Back pain—Bupropion—obesity	0.000137	0.000586	CcSEcCtD
Mesalazine—Orthostatic hypotension—Topiramate—obesity	0.000137	0.000585	CcSEcCtD
Mesalazine—Abdominal pain upper—Topiramate—obesity	0.000137	0.000585	CcSEcCtD
Mesalazine—Discomfort—Sibutramine—obesity	0.000137	0.000585	CcSEcCtD
Mesalazine—Dopamine—SLC6A4—obesity	0.000137	0.0228	CrCbGaD
Mesalazine—Muscle spasms—Bupropion—obesity	0.000136	0.000582	CcSEcCtD
Mesalazine—Infection—Orlistat—obesity	0.000136	0.000582	CcSEcCtD
Mesalazine—Dopamine—DRD2—obesity	0.000136	0.0226	CrCbGaD
Mesalazine—Breast disorder—Topiramate—obesity	0.000136	0.000579	CcSEcCtD
Mesalazine—Dry mouth—Sibutramine—obesity	0.000136	0.000579	CcSEcCtD
Mesalazine—Aspartate aminotransferase increased—Topiramate—obesity	0.000135	0.000577	CcSEcCtD
Mesalazine—Nervous system disorder—Orlistat—obesity	0.000135	0.000575	CcSEcCtD
Mesalazine—Nasopharyngitis—Topiramate—obesity	0.000134	0.000573	CcSEcCtD
Mesalazine—Confusional state—Sibutramine—obesity	0.000134	0.000572	CcSEcCtD
Mesalazine—Vision blurred—Bupropion—obesity	0.000134	0.000571	CcSEcCtD
Mesalazine—Skin disorder—Orlistat—obesity	0.000133	0.000569	CcSEcCtD
Mesalazine—Tremor—Bupropion—obesity	0.000133	0.000568	CcSEcCtD
Mesalazine—Gastritis—Topiramate—obesity	0.000133	0.000567	CcSEcCtD
Mesalazine—Oedema—Sibutramine—obesity	0.000133	0.000567	CcSEcCtD
Mesalazine—Anaphylactic shock—Sibutramine—obesity	0.000133	0.000567	CcSEcCtD
Mesalazine—Hyperhidrosis—Orlistat—obesity	0.000133	0.000567	CcSEcCtD
Mesalazine—Alanine aminotransferase increased—Topiramate—obesity	0.000132	0.000565	CcSEcCtD
Mesalazine—Infection—Sibutramine—obesity	0.000132	0.000563	CcSEcCtD
Mesalazine—Ill-defined disorder—Bupropion—obesity	0.000132	0.000562	CcSEcCtD
Mesalazine—Anaemia—Bupropion—obesity	0.000131	0.00056	CcSEcCtD
Mesalazine—Shock—Sibutramine—obesity	0.000131	0.000558	CcSEcCtD
Mesalazine—Abdominal distension—Topiramate—obesity	0.000131	0.000558	CcSEcCtD
Mesalazine—Thrombocytopenia—Sibutramine—obesity	0.00013	0.000555	CcSEcCtD
Mesalazine—Dysphagia—Topiramate—obesity	0.00013	0.000554	CcSEcCtD
Mesalazine—Asthma—Topiramate—obesity	0.00013	0.000554	CcSEcCtD
Mesalazine—Angioedema—Bupropion—obesity	0.00013	0.000554	CcSEcCtD
Mesalazine—Tachycardia—Sibutramine—obesity	0.00013	0.000554	CcSEcCtD
Mesalazine—Skin disorder—Sibutramine—obesity	0.000129	0.000551	CcSEcCtD
Mesalazine—Eosinophilia—Topiramate—obesity	0.000129	0.000548	CcSEcCtD
Mesalazine—Hyperhidrosis—Sibutramine—obesity	0.000128	0.000548	CcSEcCtD
Mesalazine—Malaise—Bupropion—obesity	0.000128	0.000546	CcSEcCtD
Mesalazine—Vertigo—Bupropion—obesity	0.000128	0.000544	CcSEcCtD
Mesalazine—Syncope—Bupropion—obesity	0.000127	0.000543	CcSEcCtD
Mesalazine—Pancreatitis—Topiramate—obesity	0.000127	0.000543	CcSEcCtD
Mesalazine—Leukopenia—Bupropion—obesity	0.000127	0.000542	CcSEcCtD
Mesalazine—Anorexia—Sibutramine—obesity	0.000127	0.000541	CcSEcCtD
Mesalazine—Angina pectoris—Topiramate—obesity	0.000126	0.00054	CcSEcCtD
Mesalazine—Palpitations—Bupropion—obesity	0.000125	0.000535	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Orlistat—obesity	0.000125	0.000534	CcSEcCtD
Mesalazine—Bronchitis—Topiramate—obesity	0.000125	0.000533	CcSEcCtD
Mesalazine—Loss of consciousness—Bupropion—obesity	0.000125	0.000532	CcSEcCtD
Mesalazine—Abdominal discomfort—Topiramate—obesity	0.000124	0.000531	CcSEcCtD
Mesalazine—Insomnia—Orlistat—obesity	0.000124	0.00053	CcSEcCtD
Mesalazine—Hypotension—Sibutramine—obesity	0.000124	0.00053	CcSEcCtD
Mesalazine—Cough—Bupropion—obesity	0.000124	0.000529	CcSEcCtD
Mesalazine—Paraesthesia—Orlistat—obesity	0.000123	0.000526	CcSEcCtD
Mesalazine—Pancytopenia—Topiramate—obesity	0.000123	0.000526	CcSEcCtD
Mesalazine—Hypertension—Bupropion—obesity	0.000123	0.000523	CcSEcCtD
Mesalazine—Dysuria—Topiramate—obesity	0.000121	0.000518	CcSEcCtD
Mesalazine—Neutropenia—Topiramate—obesity	0.000121	0.000518	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Sibutramine—obesity	0.000121	0.000517	CcSEcCtD
Mesalazine—Dyspepsia—Orlistat—obesity	0.000121	0.000516	CcSEcCtD
Mesalazine—Arthralgia—Bupropion—obesity	0.000121	0.000516	CcSEcCtD
Mesalazine—Myalgia—Bupropion—obesity	0.000121	0.000516	CcSEcCtD
Mesalazine—Chest pain—Bupropion—obesity	0.000121	0.000516	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Topiramate—obesity	0.000121	0.000515	CcSEcCtD
Mesalazine—Anxiety—Bupropion—obesity	0.00012	0.000514	CcSEcCtD
Mesalazine—Insomnia—Sibutramine—obesity	0.00012	0.000513	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.00012	0.000512	CcSEcCtD
Mesalazine—Pollakiuria—Topiramate—obesity	0.00012	0.000512	CcSEcCtD
Mesalazine—Discomfort—Bupropion—obesity	0.000119	0.00051	CcSEcCtD
Mesalazine—Decreased appetite—Orlistat—obesity	0.000119	0.000509	CcSEcCtD
Mesalazine—Paraesthesia—Sibutramine—obesity	0.000119	0.000509	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Orlistat—obesity	0.000119	0.000506	CcSEcCtD
Mesalazine—Dyspnoea—Sibutramine—obesity	0.000118	0.000506	CcSEcCtD
Mesalazine—Photosensitivity reaction—Topiramate—obesity	0.000118	0.000506	CcSEcCtD
Mesalazine—Fatigue—Orlistat—obesity	0.000118	0.000505	CcSEcCtD
Mesalazine—Dry mouth—Bupropion—obesity	0.000118	0.000504	CcSEcCtD
Mesalazine—Somnolence—Sibutramine—obesity	0.000118	0.000504	CcSEcCtD
Mesalazine—Weight increased—Topiramate—obesity	0.000118	0.000504	CcSEcCtD
Mesalazine—Weight decreased—Topiramate—obesity	0.000117	0.000501	CcSEcCtD
Mesalazine—Pain—Orlistat—obesity	0.000117	0.000501	CcSEcCtD
Mesalazine—Dyspepsia—Sibutramine—obesity	0.000117	0.000499	CcSEcCtD
Mesalazine—Confusional state—Bupropion—obesity	0.000117	0.000499	CcSEcCtD
Mesalazine—Pneumonia—Topiramate—obesity	0.000116	0.000497	CcSEcCtD
Mesalazine—Anaphylactic shock—Bupropion—obesity	0.000116	0.000494	CcSEcCtD
Mesalazine—Oedema—Bupropion—obesity	0.000116	0.000494	CcSEcCtD
Mesalazine—Infestation—Topiramate—obesity	0.000116	0.000494	CcSEcCtD
Mesalazine—Infestation NOS—Topiramate—obesity	0.000116	0.000494	CcSEcCtD
Mesalazine—Decreased appetite—Sibutramine—obesity	0.000116	0.000493	CcSEcCtD
Mesalazine—Depression—Topiramate—obesity	0.000115	0.000492	CcSEcCtD
Mesalazine—Infection—Bupropion—obesity	0.000115	0.000491	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Topiramate—obesity	0.000115	0.00049	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Sibutramine—obesity	0.000115	0.00049	CcSEcCtD
Mesalazine—Shock—Bupropion—obesity	0.000114	0.000486	CcSEcCtD
Mesalazine—Renal failure—Topiramate—obesity	0.000114	0.000486	CcSEcCtD
Mesalazine—Pain—Sibutramine—obesity	0.000114	0.000485	CcSEcCtD
Mesalazine—Constipation—Sibutramine—obesity	0.000114	0.000485	CcSEcCtD
Mesalazine—Nervous system disorder—Bupropion—obesity	0.000114	0.000485	CcSEcCtD
Mesalazine—Neuropathy peripheral—Topiramate—obesity	0.000113	0.000484	CcSEcCtD
Mesalazine—Thrombocytopenia—Bupropion—obesity	0.000113	0.000484	CcSEcCtD
Mesalazine—Feeling abnormal—Orlistat—obesity	0.000113	0.000483	CcSEcCtD
Mesalazine—Tachycardia—Bupropion—obesity	0.000113	0.000483	CcSEcCtD
Mesalazine—Stomatitis—Topiramate—obesity	0.000113	0.000481	CcSEcCtD
Mesalazine—Skin disorder—Bupropion—obesity	0.000113	0.00048	CcSEcCtD
Mesalazine—Conjunctivitis—Topiramate—obesity	0.000112	0.00048	CcSEcCtD
Mesalazine—Urinary tract infection—Topiramate—obesity	0.000112	0.00048	CcSEcCtD
Mesalazine—Gastrointestinal pain—Orlistat—obesity	0.000112	0.000479	CcSEcCtD
Mesalazine—Hyperhidrosis—Bupropion—obesity	0.000112	0.000478	CcSEcCtD
Mesalazine—Anorexia—Bupropion—obesity	0.00011	0.000471	CcSEcCtD
Mesalazine—Haematuria—Topiramate—obesity	0.00011	0.000471	CcSEcCtD
Mesalazine—Feeling abnormal—Sibutramine—obesity	0.00011	0.000467	CcSEcCtD
Mesalazine—Epistaxis—Topiramate—obesity	0.000109	0.000466	CcSEcCtD
Mesalazine—Urticaria—Orlistat—obesity	0.000109	0.000466	CcSEcCtD
Mesalazine—Gastrointestinal pain—Sibutramine—obesity	0.000109	0.000464	CcSEcCtD
Mesalazine—Sinusitis—Topiramate—obesity	0.000109	0.000463	CcSEcCtD
Mesalazine—Abdominal pain—Orlistat—obesity	0.000109	0.000463	CcSEcCtD
Mesalazine—Body temperature increased—Orlistat—obesity	0.000109	0.000463	CcSEcCtD
Mesalazine—Hypotension—Bupropion—obesity	0.000108	0.000462	CcSEcCtD
Mesalazine—Agranulocytosis—Topiramate—obesity	0.000108	0.000461	CcSEcCtD
Mesalazine—Urticaria—Sibutramine—obesity	0.000106	0.000451	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Bupropion—obesity	0.000106	0.00045	CcSEcCtD
Mesalazine—Abdominal pain—Sibutramine—obesity	0.000105	0.000448	CcSEcCtD
Mesalazine—Body temperature increased—Sibutramine—obesity	0.000105	0.000448	CcSEcCtD
Mesalazine—Insomnia—Bupropion—obesity	0.000105	0.000447	CcSEcCtD
Mesalazine—Haemoglobin—Topiramate—obesity	0.000104	0.000446	CcSEcCtD
Mesalazine—Rhinitis—Topiramate—obesity	0.000104	0.000445	CcSEcCtD
Mesalazine—Paraesthesia—Bupropion—obesity	0.000104	0.000444	CcSEcCtD
Mesalazine—Hepatitis—Topiramate—obesity	0.000104	0.000443	CcSEcCtD
Mesalazine—Haemorrhage—Topiramate—obesity	0.000104	0.000443	CcSEcCtD
Mesalazine—Dyspnoea—Bupropion—obesity	0.000103	0.000441	CcSEcCtD
Mesalazine—Pharyngitis—Topiramate—obesity	0.000103	0.00044	CcSEcCtD
Mesalazine—Somnolence—Bupropion—obesity	0.000103	0.00044	CcSEcCtD
Mesalazine—Urinary tract disorder—Topiramate—obesity	0.000103	0.000438	CcSEcCtD
Mesalazine—Oedema peripheral—Topiramate—obesity	0.000102	0.000437	CcSEcCtD
Mesalazine—Connective tissue disorder—Topiramate—obesity	0.000102	0.000436	CcSEcCtD
Mesalazine—Dyspepsia—Bupropion—obesity	0.000102	0.000435	CcSEcCtD
Mesalazine—Urethral disorder—Topiramate—obesity	0.000102	0.000435	CcSEcCtD
Mesalazine—Hypersensitivity—Orlistat—obesity	0.000101	0.000432	CcSEcCtD
Mesalazine—Decreased appetite—Bupropion—obesity	0.000101	0.00043	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Bupropion—obesity	0.0001	0.000427	CcSEcCtD
Mesalazine—Fatigue—Bupropion—obesity	9.99e-05	0.000426	CcSEcCtD
Mesalazine—Pain—Bupropion—obesity	9.91e-05	0.000423	CcSEcCtD
Mesalazine—Constipation—Bupropion—obesity	9.91e-05	0.000423	CcSEcCtD
Mesalazine—Asthenia—Orlistat—obesity	9.85e-05	0.00042	CcSEcCtD
Mesalazine—Erythema multiforme—Topiramate—obesity	9.82e-05	0.000419	CcSEcCtD
Mesalazine—Hypersensitivity—Sibutramine—obesity	9.79e-05	0.000418	CcSEcCtD
Mesalazine—Pruritus—Orlistat—obesity	9.72e-05	0.000415	CcSEcCtD
Mesalazine—Eye disorder—Topiramate—obesity	9.71e-05	0.000414	CcSEcCtD
Mesalazine—Salicylic acid—PTGS2—obesity	9.7e-05	0.0161	CrCbGaD
Mesalazine—Tinnitus—Topiramate—obesity	9.69e-05	0.000413	CcSEcCtD
Mesalazine—Cardiac disorder—Topiramate—obesity	9.64e-05	0.000411	CcSEcCtD
Mesalazine—Feeling abnormal—Bupropion—obesity	9.55e-05	0.000407	CcSEcCtD
Mesalazine—Asthenia—Sibutramine—obesity	9.53e-05	0.000407	CcSEcCtD
Mesalazine—Gastrointestinal pain—Bupropion—obesity	9.47e-05	0.000404	CcSEcCtD
Mesalazine—Angiopathy—Topiramate—obesity	9.43e-05	0.000402	CcSEcCtD
Mesalazine—Pruritus—Sibutramine—obesity	9.4e-05	0.000401	CcSEcCtD
Mesalazine—Diarrhoea—Orlistat—obesity	9.4e-05	0.000401	CcSEcCtD
Mesalazine—Immune system disorder—Topiramate—obesity	9.38e-05	0.0004	CcSEcCtD
Mesalazine—Mediastinal disorder—Topiramate—obesity	9.36e-05	0.0004	CcSEcCtD
Mesalazine—Chills—Topiramate—obesity	9.32e-05	0.000398	CcSEcCtD
Mesalazine—Urticaria—Bupropion—obesity	9.2e-05	0.000393	CcSEcCtD
Mesalazine—Alopecia—Topiramate—obesity	9.18e-05	0.000392	CcSEcCtD
Mesalazine—Abdominal pain—Bupropion—obesity	9.16e-05	0.000391	CcSEcCtD
Mesalazine—Body temperature increased—Bupropion—obesity	9.16e-05	0.000391	CcSEcCtD
Mesalazine—Mental disorder—Topiramate—obesity	9.1e-05	0.000388	CcSEcCtD
Mesalazine—Diarrhoea—Sibutramine—obesity	9.09e-05	0.000388	CcSEcCtD
Mesalazine—Dizziness—Orlistat—obesity	9.08e-05	0.000388	CcSEcCtD
Mesalazine—Erythema—Topiramate—obesity	9.04e-05	0.000386	CcSEcCtD
Mesalazine—Flatulence—Topiramate—obesity	8.91e-05	0.00038	CcSEcCtD
Mesalazine—Tension—Topiramate—obesity	8.87e-05	0.000379	CcSEcCtD
Mesalazine—Dysgeusia—Topiramate—obesity	8.86e-05	0.000378	CcSEcCtD
Mesalazine—Dizziness—Sibutramine—obesity	8.79e-05	0.000375	CcSEcCtD
Mesalazine—Nervousness—Topiramate—obesity	8.78e-05	0.000375	CcSEcCtD
Mesalazine—Back pain—Topiramate—obesity	8.75e-05	0.000373	CcSEcCtD
Mesalazine—Vomiting—Orlistat—obesity	8.73e-05	0.000373	CcSEcCtD
Mesalazine—Muscle spasms—Topiramate—obesity	8.7e-05	0.000371	CcSEcCtD
Mesalazine—Rash—Orlistat—obesity	8.66e-05	0.00037	CcSEcCtD
Mesalazine—Dermatitis—Orlistat—obesity	8.65e-05	0.000369	CcSEcCtD
Mesalazine—Salicylic acid—ALB—obesity	8.65e-05	0.0144	CrCbGaD
Mesalazine—Headache—Orlistat—obesity	8.6e-05	0.000367	CcSEcCtD
Mesalazine—Hypersensitivity—Bupropion—obesity	8.54e-05	0.000364	CcSEcCtD
Mesalazine—Vision blurred—Topiramate—obesity	8.52e-05	0.000364	CcSEcCtD
Mesalazine—Tremor—Topiramate—obesity	8.47e-05	0.000362	CcSEcCtD
Mesalazine—Vomiting—Sibutramine—obesity	8.45e-05	0.000361	CcSEcCtD
Mesalazine—Ill-defined disorder—Topiramate—obesity	8.39e-05	0.000358	CcSEcCtD
Mesalazine—Rash—Sibutramine—obesity	8.38e-05	0.000358	CcSEcCtD
Mesalazine—Dermatitis—Sibutramine—obesity	8.37e-05	0.000357	CcSEcCtD
Mesalazine—Anaemia—Topiramate—obesity	8.36e-05	0.000357	CcSEcCtD
Mesalazine—Headache—Sibutramine—obesity	8.33e-05	0.000355	CcSEcCtD
Mesalazine—Asthenia—Bupropion—obesity	8.31e-05	0.000355	CcSEcCtD
Mesalazine—Pruritus—Bupropion—obesity	8.2e-05	0.00035	CcSEcCtD
Mesalazine—Nausea—Orlistat—obesity	8.16e-05	0.000348	CcSEcCtD
Mesalazine—Malaise—Topiramate—obesity	8.16e-05	0.000348	CcSEcCtD
Mesalazine—Vertigo—Topiramate—obesity	8.13e-05	0.000347	CcSEcCtD
Mesalazine—Syncope—Topiramate—obesity	8.11e-05	0.000346	CcSEcCtD
Mesalazine—Leukopenia—Topiramate—obesity	8.1e-05	0.000345	CcSEcCtD
Mesalazine—Palpitations—Topiramate—obesity	7.99e-05	0.000341	CcSEcCtD
Mesalazine—Loss of consciousness—Topiramate—obesity	7.95e-05	0.000339	CcSEcCtD
Mesalazine—Diarrhoea—Bupropion—obesity	7.93e-05	0.000338	CcSEcCtD
Mesalazine—Nausea—Sibutramine—obesity	7.89e-05	0.000337	CcSEcCtD
Mesalazine—Cough—Topiramate—obesity	7.89e-05	0.000337	CcSEcCtD
Mesalazine—Hypertension—Topiramate—obesity	7.81e-05	0.000333	CcSEcCtD
Mesalazine—Arthralgia—Topiramate—obesity	7.7e-05	0.000329	CcSEcCtD
Mesalazine—Chest pain—Topiramate—obesity	7.7e-05	0.000329	CcSEcCtD
Mesalazine—Myalgia—Topiramate—obesity	7.7e-05	0.000329	CcSEcCtD
Mesalazine—Anxiety—Topiramate—obesity	7.67e-05	0.000327	CcSEcCtD
Mesalazine—Dizziness—Bupropion—obesity	7.66e-05	0.000327	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	7.65e-05	0.000326	CcSEcCtD
Mesalazine—Discomfort—Topiramate—obesity	7.61e-05	0.000325	CcSEcCtD
Mesalazine—Dry mouth—Topiramate—obesity	7.53e-05	0.000321	CcSEcCtD
Mesalazine—Confusional state—Topiramate—obesity	7.44e-05	0.000318	CcSEcCtD
Mesalazine—Oedema—Topiramate—obesity	7.38e-05	0.000315	CcSEcCtD
Mesalazine—Vomiting—Bupropion—obesity	7.37e-05	0.000314	CcSEcCtD
Mesalazine—Infection—Topiramate—obesity	7.33e-05	0.000313	CcSEcCtD
Mesalazine—Rash—Bupropion—obesity	7.3e-05	0.000312	CcSEcCtD
Mesalazine—Dermatitis—Bupropion—obesity	7.3e-05	0.000311	CcSEcCtD
Mesalazine—Shock—Topiramate—obesity	7.26e-05	0.00031	CcSEcCtD
Mesalazine—Headache—Bupropion—obesity	7.26e-05	0.00031	CcSEcCtD
Mesalazine—Nervous system disorder—Topiramate—obesity	7.24e-05	0.000309	CcSEcCtD
Mesalazine—Thrombocytopenia—Topiramate—obesity	7.23e-05	0.000308	CcSEcCtD
Mesalazine—Tachycardia—Topiramate—obesity	7.2e-05	0.000307	CcSEcCtD
Mesalazine—Skin disorder—Topiramate—obesity	7.17e-05	0.000306	CcSEcCtD
Mesalazine—Hyperhidrosis—Topiramate—obesity	7.14e-05	0.000305	CcSEcCtD
Mesalazine—Anorexia—Topiramate—obesity	7.04e-05	0.0003	CcSEcCtD
Mesalazine—Hypotension—Topiramate—obesity	6.9e-05	0.000294	CcSEcCtD
Mesalazine—Nausea—Bupropion—obesity	6.88e-05	0.000294	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Topiramate—obesity	6.72e-05	0.000287	CcSEcCtD
Mesalazine—Insomnia—Topiramate—obesity	6.68e-05	0.000285	CcSEcCtD
Mesalazine—Paraesthesia—Topiramate—obesity	6.63e-05	0.000283	CcSEcCtD
Mesalazine—Dyspnoea—Topiramate—obesity	6.58e-05	0.000281	CcSEcCtD
Mesalazine—Somnolence—Topiramate—obesity	6.56e-05	0.00028	CcSEcCtD
Mesalazine—Dyspepsia—Topiramate—obesity	6.5e-05	0.000277	CcSEcCtD
Mesalazine—Decreased appetite—Topiramate—obesity	6.42e-05	0.000274	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Topiramate—obesity	6.37e-05	0.000272	CcSEcCtD
Mesalazine—Fatigue—Topiramate—obesity	6.36e-05	0.000272	CcSEcCtD
Mesalazine—Constipation—Topiramate—obesity	6.31e-05	0.000269	CcSEcCtD
Mesalazine—Pain—Topiramate—obesity	6.31e-05	0.000269	CcSEcCtD
Mesalazine—Feeling abnormal—Topiramate—obesity	6.08e-05	0.00026	CcSEcCtD
Mesalazine—Gastrointestinal pain—Topiramate—obesity	6.04e-05	0.000258	CcSEcCtD
Mesalazine—Urticaria—Topiramate—obesity	5.86e-05	0.00025	CcSEcCtD
Mesalazine—Abdominal pain—Topiramate—obesity	5.83e-05	0.000249	CcSEcCtD
Mesalazine—Body temperature increased—Topiramate—obesity	5.83e-05	0.000249	CcSEcCtD
Mesalazine—Hypersensitivity—Topiramate—obesity	5.44e-05	0.000232	CcSEcCtD
Mesalazine—Asthenia—Topiramate—obesity	5.3e-05	0.000226	CcSEcCtD
Mesalazine—Pruritus—Topiramate—obesity	5.22e-05	0.000223	CcSEcCtD
Mesalazine—Diarrhoea—Topiramate—obesity	5.05e-05	0.000216	CcSEcCtD
Mesalazine—Dizziness—Topiramate—obesity	4.88e-05	0.000208	CcSEcCtD
Mesalazine—Vomiting—Topiramate—obesity	4.69e-05	0.0002	CcSEcCtD
Mesalazine—Rash—Topiramate—obesity	4.65e-05	0.000199	CcSEcCtD
Mesalazine—Dermatitis—Topiramate—obesity	4.65e-05	0.000198	CcSEcCtD
Mesalazine—Headache—Topiramate—obesity	4.62e-05	0.000197	CcSEcCtD
Mesalazine—Nausea—Topiramate—obesity	4.38e-05	0.000187	CcSEcCtD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—obesity	6.91e-06	3.55e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—IL6—obesity	6.85e-06	3.52e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—LPL—obesity	6.83e-06	3.51e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3R1—obesity	6.83e-06	3.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GNB3—obesity	6.81e-06	3.5e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—COMT—obesity	6.79e-06	3.49e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FOXO1—obesity	6.78e-06	3.49e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—FASN—obesity	6.77e-06	3.48e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RPS6KB1—obesity	6.77e-06	3.48e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—TYK2—obesity	6.76e-06	3.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT2—obesity	6.75e-06	3.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—BCHE—obesity	6.75e-06	3.47e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GNB3—obesity	6.7e-06	3.44e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARGC1A—obesity	6.7e-06	3.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF2—obesity	6.68e-06	3.43e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FOXO3—obesity	6.68e-06	3.43e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—HMOX1—obesity	6.67e-06	3.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3R1—obesity	6.64e-06	3.41e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT2—obesity	6.63e-06	3.41e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GNAS—obesity	6.63e-06	3.4e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CG—obesity	6.59e-06	3.38e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GNAS—obesity	6.52e-06	3.35e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP2E1—obesity	6.51e-06	3.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CD—obesity	6.49e-06	3.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOB—obesity	6.49e-06	3.33e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NQO1—obesity	6.43e-06	3.31e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—SERPINE1—obesity	6.42e-06	3.3e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PIK3CA—obesity	6.41e-06	3.29e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—BCL2—obesity	6.39e-06	3.28e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOB—obesity	6.39e-06	3.28e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CD—obesity	6.37e-06	3.27e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCL5—obesity	6.34e-06	3.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IFNG—obesity	6.33e-06	3.25e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—AKT1—obesity	6.32e-06	3.25e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—obesity	6.3e-06	3.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PRKCD—obesity	6.3e-06	3.23e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—POMC—obesity	6.27e-06	3.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—TYK2—obesity	6.24e-06	3.21e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—INS—obesity	6.23e-06	3.2e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—LPL—obesity	6.2e-06	3.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—RHOA—obesity	6.19e-06	3.18e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SLC2A4—obesity	6.17e-06	3.17e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GCG—obesity	6.17e-06	3.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HTR2A—obesity	6.16e-06	3.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PIK3CA—obesity	6.16e-06	3.16e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—C3—obesity	6.15e-06	3.16e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FOXO1—obesity	6.15e-06	3.16e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RPS6KB1—obesity	6.14e-06	3.16e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TYK2—obesity	6.13e-06	3.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3R1—obesity	6.13e-06	3.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOS3—obesity	6.13e-06	3.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MTOR—obesity	6.13e-06	3.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CB—obesity	6.13e-06	3.15e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—LPL—obesity	6.1e-06	3.13e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYCS—obesity	6.09e-06	3.13e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOB—obesity	6.05e-06	3.11e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3R1—obesity	6.02e-06	3.09e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GGT1—obesity	5.97e-06	3.07e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GOT1—obesity	5.97e-06	3.07e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GPX1—obesity	5.95e-06	3.06e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NCOA1—obesity	5.89e-06	3.02e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IRS2—obesity	5.85e-06	3.01e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AGT—obesity	5.85e-06	3e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PIK3CA—obesity	5.81e-06	2.99e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—STK11—obesity	5.8e-06	2.98e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP19A1—obesity	5.8e-06	2.98e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—BCL2—obesity	5.79e-06	2.98e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CD36—obesity	5.79e-06	2.98e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CD—obesity	5.79e-06	2.97e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—LPL—obesity	5.78e-06	2.97e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IFNG—obesity	5.74e-06	2.95e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FOXO1—obesity	5.74e-06	2.95e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APOE—obesity	5.73e-06	2.94e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—LEP—obesity	5.73e-06	2.94e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ALB—obesity	5.71e-06	2.94e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PRKCD—obesity	5.71e-06	2.93e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6—obesity	5.68e-06	2.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CAV1—obesity	5.68e-06	2.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APOA1—obesity	5.66e-06	2.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CB—obesity	5.66e-06	2.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MTOR—obesity	5.66e-06	2.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL1B—obesity	5.65e-06	2.9e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—obesity	5.6e-06	2.88e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HTR2A—obesity	5.59e-06	2.87e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PIK3CA—obesity	5.58e-06	2.87e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—C3—obesity	5.58e-06	2.87e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MTOR—obesity	5.56e-06	2.85e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CB—obesity	5.56e-06	2.85e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—MTHFR—obesity	5.49e-06	2.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ESR1—obesity	5.47e-06	2.81e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3R1—obesity	5.47e-06	2.81e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—NOS3—obesity	5.47e-06	2.81e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PRKCB—obesity	5.4e-06	2.78e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—F2—obesity	5.4e-06	2.78e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—COMT—obesity	5.39e-06	2.77e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARA—obesity	5.39e-06	2.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—BAD—obesity	5.34e-06	2.74e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PRKCD—obesity	5.33e-06	2.74e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARGC1A—obesity	5.32e-06	2.73e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GNB3—obesity	5.32e-06	2.73e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IRS2—obesity	5.31e-06	2.73e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AGT—obesity	5.3e-06	2.72e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—HMOX1—obesity	5.29e-06	2.72e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—obesity	5.24e-06	2.69e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AGT—obesity	5.22e-06	2.68e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTHFR—obesity	5.2e-06	2.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOE—obesity	5.19e-06	2.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—LEP—obesity	5.19e-06	2.67e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK8—obesity	5.18e-06	2.66e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GNAS—obesity	5.18e-06	2.66e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CG—obesity	5.17e-06	2.66e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6—obesity	5.15e-06	2.65e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CAV1—obesity	5.15e-06	2.64e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOA1—obesity	5.13e-06	2.64e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL1B—obesity	5.12e-06	2.63e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOE—obesity	5.11e-06	2.63e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IRS1—obesity	5.11e-06	2.63e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOB—obesity	5.07e-06	2.6e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CAV1—obesity	5.06e-06	2.6e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOA1—obesity	5.05e-06	2.6e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CB—obesity	5.05e-06	2.59e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—obesity	5.03e-06	2.58e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—obesity	5e-06	2.57e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CA—obesity	4.97e-06	2.55e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ESR1—obesity	4.96e-06	2.55e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IRS2—obesity	4.95e-06	2.54e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—POMC—obesity	4.92e-06	2.53e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PRKCB—obesity	4.9e-06	2.52e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—F2—obesity	4.9e-06	2.52e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—INS—obesity	4.89e-06	2.51e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOE—obesity	4.85e-06	2.49e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—LPL—obesity	4.84e-06	2.49e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—BAD—obesity	4.84e-06	2.49e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—obesity	4.84e-06	2.49e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCL2—obesity	4.81e-06	2.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CAV1—obesity	4.8e-06	2.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOA1—obesity	4.79e-06	2.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—obesity	4.75e-06	2.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—STAT3—obesity	4.73e-06	2.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF1—obesity	4.73e-06	2.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT2—obesity	4.73e-06	2.43e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GPX1—obesity	4.72e-06	2.43e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK8—obesity	4.7e-06	2.41e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CG—obesity	4.69e-06	2.41e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—obesity	4.66e-06	2.39e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IRS1—obesity	4.63e-06	2.38e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CG—obesity	4.61e-06	2.37e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CD36—obesity	4.6e-06	2.36e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—obesity	4.56e-06	2.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CD—obesity	4.54e-06	2.33e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—BAD—obesity	4.52e-06	2.32e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SERPINE1—obesity	4.49e-06	2.31e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—POMC—obesity	4.46e-06	2.29e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARG—obesity	4.45e-06	2.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—INS—obesity	4.44e-06	2.28e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—POMC—obesity	4.39e-06	2.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TYK2—obesity	4.37e-06	2.25e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—STAT3—obesity	4.37e-06	2.25e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—INS—obesity	4.37e-06	2.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCL2—obesity	4.37e-06	2.24e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—MTHFR—obesity	4.36e-06	2.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RHOA—obesity	4.34e-06	2.23e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IRS1—obesity	4.32e-06	2.22e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—STAT3—obesity	4.29e-06	2.21e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF1—obesity	4.29e-06	2.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOS3—obesity	4.29e-06	2.2e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3R1—obesity	4.29e-06	2.2e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT2—obesity	4.29e-06	2.2e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARA—obesity	4.28e-06	2.2e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AGT—obesity	4.14e-06	2.13e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—INS—obesity	4.14e-06	2.13e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CD—obesity	4.12e-06	2.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SERPINE1—obesity	4.08e-06	2.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—obesity	4.06e-06	2.09e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—obesity	4.06e-06	2.09e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOE—obesity	4.06e-06	2.08e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CD—obesity	4.06e-06	2.08e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—TGFB1—obesity	4.05e-06	2.08e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CAV1—obesity	4.02e-06	2.07e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOA1—obesity	4.01e-06	2.06e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ALB—obesity	4e-06	2.06e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT2—obesity	4e-06	2.06e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TYK2—obesity	3.96e-06	2.04e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MTOR—obesity	3.96e-06	2.04e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CB—obesity	3.96e-06	2.04e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RHOA—obesity	3.93e-06	2.02e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOS3—obesity	3.89e-06	2e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3R1—obesity	3.89e-06	2e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CD—obesity	3.84e-06	1.98e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—obesity	3.84e-06	1.97e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NOS3—obesity	3.83e-06	1.97e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3R1—obesity	3.83e-06	1.97e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SERPINE1—obesity	3.8e-06	1.95e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CA—obesity	3.73e-06	1.92e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TYK2—obesity	3.7e-06	1.9e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RHOA—obesity	3.67e-06	1.88e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CG—obesity	3.66e-06	1.88e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3R1—obesity	3.63e-06	1.87e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS3—obesity	3.63e-06	1.87e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MTOR—obesity	3.59e-06	1.85e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CB—obesity	3.59e-06	1.85e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CB—obesity	3.53e-06	1.82e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARG—obesity	3.53e-06	1.82e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—obesity	3.5e-06	1.8e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—POMC—obesity	3.49e-06	1.79e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—INS—obesity	3.47e-06	1.78e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CA—obesity	3.45e-06	1.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—obesity	3.44e-06	1.77e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CA—obesity	3.39e-06	1.74e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTOR—obesity	3.35e-06	1.72e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CB—obesity	3.35e-06	1.72e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK8—obesity	3.35e-06	1.72e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6—obesity	3.31e-06	1.7e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—obesity	3.23e-06	1.66e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CD—obesity	3.22e-06	1.65e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ALB—obesity	3.18e-06	1.63e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—obesity	3.12e-06	1.6e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CA—obesity	3.08e-06	1.58e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STAT3—obesity	3.06e-06	1.57e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6—obesity	3.05e-06	1.57e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—obesity	3.05e-06	1.57e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3R1—obesity	3.04e-06	1.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NOS3—obesity	3.04e-06	1.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK8—obesity	3.04e-06	1.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6—obesity	3e-06	1.54e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—obesity	2.84e-06	1.46e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TGFB1—obesity	2.84e-06	1.46e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—obesity	2.82e-06	1.45e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CB—obesity	2.81e-06	1.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STAT3—obesity	2.78e-06	1.43e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—obesity	2.77e-06	1.42e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—STAT3—obesity	2.59e-06	1.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—obesity	2.58e-06	1.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TGFB1—obesity	2.57e-06	1.32e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—obesity	2.51e-06	1.29e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CA—obesity	2.41e-06	1.24e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—obesity	2.41e-06	1.24e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TGFB1—obesity	2.4e-06	1.23e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CA—obesity	2.19e-06	1.12e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CA—obesity	2.15e-06	1.11e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6—obesity	2.14e-06	1.1e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CA—obesity	2.04e-06	1.05e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—obesity	1.97e-06	1.01e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6—obesity	1.94e-06	9.96e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6—obesity	1.81e-06	9.29e-06	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—obesity	1.79e-06	9.19e-06	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—obesity	1.76e-06	9.04e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CA—obesity	1.71e-06	8.79e-06	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—obesity	1.67e-06	8.57e-06	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—obesity	1.4e-06	7.18e-06	CbGpPWpGaD
